Immune Evasion of SARS-CoV-2 Omicron Subvariants
Since the SARS-CoV-2 Omicron variant (B.1.1.529) was declared a variant of concern (VOC) by the WHO on 24 November 2021, it has caused another global surge of cases. With extensive mutations in its spike glycoprotein, Omicron gained substantial capabilities to evade the antiviral immunity provided b...
Main Authors: | Hanzhong Ke, Matthew R. Chang, Wayne A. Marasco |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/9/1545 |
Similar Items
-
Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants
by: Yaning Li, et al.
Published: (2023-06-01) -
An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022-12-01) -
Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
by: Srijan Chatterjee, et al.
Published: (2023-06-01) -
Molecular Evolutionary Analyses of the Spike Protein Gene and Spike Protein in the SARS-CoV-2 Omicron Subvariants
by: Norika Nagasawa, et al.
Published: (2023-09-01) -
Computational Investigation of Selected Spike Protein Mutations in SARS-CoV-2: Delta, Omicron, and Some Circulating Subvariants
by: Urmi Roy
Published: (2023-12-01)